Smilow Cancer Hospital at Yale New Haven

New Haven, CT

Sorting 11 by

Accepting patients

RENEW

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  • Activin Receptor IIA Inhibitor
  • Placebo
  • Closed Label (Masked)
  • Phase 3

Accepting patients

ICP-248 With Azacitidine

A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.
  • BCL-2 Inhibitor
  • Phase 1

Accepting patients

AK117/Placebo with Azacitidine

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
  • Monoclonal Antibody
  • CD47
  • Closed Label (Masked)
  • Randomization
  • Placebo
  • Phase 2

Accepting patients

AZTOUND

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
  • DNMT1 Inhibitor
  • Phase 2/3
  • Has results

Accepting patients

MIDAS

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (MIDAS)
  • JAK1 Inhibitor
  • ACVR1 Inhibitor
  • JAK2 Inhibitor
  • Randomization
  • Phase 2

Accepting patients

DarbeLus

A Phase II Study of Luspatercept Plus Darbepoetin Alfa in Non-mutated SF3B1 Lower-risk Myelodysplastic Syndromes
  • Red Blood Cell Stimulant
  • Phase 2

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
  • Phase 1/2

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
  • Genetic Sequencing
  • Phase 2

Accepting patients

Cirtuvivint

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
  • Tyrosine Kinase (TK) Inhibitor
  • Dual Specificity TK Inhibitor (DYRK)
  • CLK Inhibitor
  • Phase 1

Accepting patients

TCR Engineered Donor T-Cells

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
  • T Cell (Allogeneic)
  • Phase 1
  • Has results